Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

National Cancer Institute (NCI)

Status: Enrolling

Conditions: Breast Carcinoma

Treatments: Other: Laboratory Biomarker Analysis

Study type: Observational

Funder types: NIH

Identifiers

NCT02610413

U10CA180820 (U.S. NIH Grant/Contract)

ECOG-E5103T2

NCI-2013-02289 (Registry Identifier)

E5103T2 (Other Identifier)

Details and patient eligibility

About

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.

Full description

PRIMARY OBJECTIVES:

I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103).

OUTLINE:

Previously collected germline DNA samples are analyzed via whole exome sequencing.

Enrollment: 354 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• European American patients with deoxyribonucleic acid (DNA) available and designated case or control
• Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
• Patients who did not develop hypertension following a full course of treatment with bevacizumab

Trial design

354 participants in 1 patient group

Ancillary-Correlative (whole exome sequencing)

Description:

Previously collected germline DNA samples are analyzed via whole exome sequencing.

Treatment:

Other: Laboratory Biomarker Analysis